LONDON, UNITED KINGDOM / ACCESS CABLE / July 29, 2022 / Poolbeg Pharmacy (AIM:POLB)(OTCQB:POLBF) (‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique light capital clinical model, has appointed Singer Capital Markets as a Joint Broker with effect. finnCap Ltd will continue to act as appointed adviser and joint broker with J&E Davy as additional joint broker.
– Ends –
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+44 (0) 207 183 1499
finnCap Ltd (appointed adviser and joint broker)
Geoff Nash James Thompson Charlie Beeson
Richard Chambers, Sunila de Silva (ECM), Nigel Birks
+44 (0) 207 220 0500
J&E Davy (joint broker)
Anthony Farrell, Niall Gilchrist
+353 (0) 1 679 6363
Singer Capital Markets (joint broker)
Phil Davies, Sam Butcher
+44 (0)20 7496 3000
Melanie Toyne Sewell Rozi Morris Tim Field
+44 (0) 20 7457 2020
About Poolbeg Pharma
Poolbeg Pharma is a clinical-stage infectious disease pharmaceutical company, with a capital-light clinical model that aims to develop multiple products faster and more cost-effectively than the conventional biotech model. The London-based company is led by a team with a track record of creating and delivering shareholder value and aspires to become a store” for Big Pharma looking for mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious diseases have become one of the fastest growing pharmaceutical markets and are expected to exceed $250 billion by 2025.
With your initial assets of open orphan plc, an industry-leading company in human challenge trials and infectious diseases, Poolbeg has access to insights, experience and clinical data from over 20 years of human challenge trials. The Company is using this knowledge to acquire new assets, as well as to reposition clinical-stage products, reducing costs and risks. Among its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) that has started its human LPS challenge trial with results expected by the end of 2022; a first-in-class RNA-based immunotherapy delivered intranasally for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The company is also developing an oral vaccine delivery platform and advancing two artificial intelligence (AI) drug discovery programs to accelerate the power of its biobank and human challenge model data, with results from the first program expected to the fourth quarter of 2022.
For more information, please go to www.poolbegpharma.com or follow us on LinkedIn Y Twitter @PoolbegPharma.
This information is provided by RNS, the news service of the London Values Exchange. RNS is approved by the Financial Conduct Authority to act as a primary information provider in the UK. Terms and conditions may apply regarding the use and distribution of this information. For more information contact [email protected] or visit www.rns.com.
FONT: Poolbeg Pharma PLC
See source version at access cable.com: